Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEWTON, Mass., Dec. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price […]
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...
Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among […]
Karyopharm Therapeutics (NASDAQ:KPTI – Free Report) had its price target cut by Royal Bank of Canada from $4.00 to $3.00 in a report published on Friday morning, Benzinga reports. They currently have an outperform rating on the stock. Several other equities analysts have also commented on the company. Wedbush reiterated a neutral rating and issued […]